MDG1.DE Medigene AG XETRA -27% pre-market 12 Feb 2026: Oversold bounce risk-reward

The MDG1.DE stock is trading pre-market at €0.13, after a heavy intraday sell-off of -27.64% on volume of 189,470 shares. This drop pushed the share price toward the year low of €0.11, creating an oversold bounce setup in XETRA trading in Germany. Short-term traders should watch the spike in relative volume (4.39x) and the gap below the 50-day average of €1.41. We outline technical triggers, balance-sheet context, and model-based price targets for an informed entry in this high-volatility biotech name.

MDG1.DE stock: price action and volume

Price collapsed to €0.13 after opening at €0.16 and trading between €0.08 and €0.16 today. The move came with 189,470 shares changing hands versus an average of 43,152, indicating panic selling into low liquidity.

That volume spike and the relative volume of 4.39 suggest short-term exhaustion. For an oversold bounce strategy, intraday follow-through above €0.15 and reversion toward €0.30 are key levels to confirm a relief rally.

MDG1.DE stock: fundamentals and valuation

Medigene AG (MDG1.DE) reports EPS -€1.21 and a negative PE ratio near -0.11, reflecting losses typical in early-stage biotech. The company has €1.36 cash per share and book value €1.72 per share, while market price sits far below both measures.

Price to book is 0.08, and price-to-sales is 0.33, signaling deep market discounting of future prospects. Current ratio of 2.53 shows short-term liquidity cover despite negative operating cash flow per share of -€1.23.

MDG1.DE stock: technical setup and risk levels

Short-term technicals show the stock trading well below the 50-day (€1.41) and 200-day (€1.66) averages. That gap confirms a long-term downtrend but creates bounce targets on intraday mean reversion.

Key levels: support €0.11 (year low), initial resistance €0.15, and stronger resistance €0.30. A close below €0.11 raises the risk of further downside. Use tight stops given high volatility.

Meyka AI rates MDG1.DE with a score out of 100

Meyka AI rates MDG1.DE with a score of 61.89 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects cash cushion and low market cap, but penalizes weak earnings and tight liquidity.

These grades are model outputs and not financial advice. They are not guaranteed and should complement your research.

Meyka AI’s forecast model and targets for MDG1.DE stock

Meyka AI’s forecast model projects a near-term relief target of €0.30, implying +124.74% from the current €0.13. A 12-month recovery scenario targets €0.80, implying +499.63% upside versus current price.

Downside risk remains: a slide to the year low €0.11 implies -17.61%. Forecasts are model-based projections and not guarantees. Position sizing must reflect the speculative nature of this biotech name.

MDG1.DE stock: catalysts, sector context and trade plan

Near-term catalysts include clinical updates and partner announcements. Medigene’s partnerships and pipeline milestones typically move the stock more than macro trends.

Healthcare sector YTD is +0.52%, offering no strong tailwind. For an oversold bounce trade, consider a small starter position with a stop below €0.11, scale out at €0.30, and re-evaluate above €0.80 for longer-term exposure. For company filings see the official site and company profile Medigene website and Medigene LinkedIn.

Final Thoughts

MDG1.DE stock shows an oversold bounce opportunity after a sharp pre-market sell-off to €0.13 on heavy volume. The trade is short-term and high-risk, driven by liquidity squeezes, a wide gap below the 50-day average, and biotech event risk. Meyka AI’s models suggest a near-term bounce target of €0.30 (+124.74%) and a more optimistic 12-month scenario of €0.80 (+499.63%). Key fundamentals include EPS -€1.21, cash per share €1.36, and a low price-to-book of 0.08, which give some balance-sheet support but do not eliminate execution risk.

If you trade an oversold bounce, size positions tightly and set stops under the €0.11 year low. Watch for confirmation in volume and a close back above €0.15 before adding. Remember that forecasts are model-based projections and not guarantees. Meyka AI provides this AI-powered market analysis to guide risk-aware entries, not to give investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.